Lamivudine/abacavir

Excerpt

A multi-centre, open label, non-interventional post-marketing surveillance performed between July 2011 and July 2017 in Korea described 13 men and 3 female patients [including 15 patients aged 32−70 years; age of the remaining one patient not stated], who experienced nausea (3 patients), diarrhoea (2 patients), hypertriglyceridaemia (2 patients), pruritic rash (2 patients), rash (1 patient), oedema (1 patient), dyslipidaemia (1 patient), skin eruption (1 patient), skin burning sensation (1 patient), alopecia (1 patient) or nausea, vomiting, headache, febrile sensation and giddiness (1 patient) as allergic reactions or suspected hypersensitivity to treatment with lamivudine/abacavir for HIV-1. …